A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
More...
FDA staff note deaths in Pfizer bone drug study
The Supreme Court on May 4 reinstated mail-order access to the widely used abortion drug mifepristone,...
At the MAHA Institute's "Mental Health & Overmedicalization Summit" in the nation's capital, the Health and...
Three people have died in an outbreak of a dangerous respiratory virus on a cruise ship...
